HUP0401167A2 - Hiszton-dezacetiláz enzimet gátló hidroxámsav-származékok, mint új, citokin szintézist gátló gyulladás elleni gyógyszerek - Google Patents

Hiszton-dezacetiláz enzimet gátló hidroxámsav-származékok, mint új, citokin szintézist gátló gyulladás elleni gyógyszerek

Info

Publication number
HUP0401167A2
HUP0401167A2 HU0401167A HUP0401167A HUP0401167A2 HU P0401167 A2 HUP0401167 A2 HU P0401167A2 HU 0401167 A HU0401167 A HU 0401167A HU P0401167 A HUP0401167 A HU P0401167A HU P0401167 A2 HUP0401167 A2 HU P0401167A2
Authority
HU
Hungary
Prior art keywords
inhibiting
hydroxamic acid
histone deacetylase
inflammatory drugs
derivatives
Prior art date
Application number
HU0401167A
Other languages
English (en)
Inventor
Paolo Mascagni
Flavio Leoni
Giulia Porro
Paolo Pagani
Giancarlo Dona'
Pietro Pozzi
Charles Dinarello
Giamila Fantuzzi
Britta Siegmund
Leonid Reznikov
Philip Bufler
Soo-Hyun Kim
Original Assignee
Italfarmaco S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco S.P.A. filed Critical Italfarmaco S.P.A.
Publication of HUP0401167A2 publication Critical patent/HUP0401167A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány hiszton-dezacetiláz enzimet gátló hatásúhidroxámsavszármazékok felhasználására vonatkozik gyulladásgátlógyógyszerek előállítására. Ilyen hidroxámsavszármazékok például aszuberoil-anilid-hidroxámsav (SAHA), a trikosztatin (TSA) és az N-hidroxi-3-[3-(hidroxi-amino)-3-oxo-l-propenil]-benzamid (CBHA). Ezekközül a találmányban elsősorban a két elsőt alkalmazzák, amelyekgátolják a gyulladást okozó citokinek szintézisét. A betegségek,amelyek a találmány szerint előállított gyógyszerekkel kezelhetők,gyulladásos és/vagy autoimmun-alapúak. Ó
HU0401167A 2001-08-07 2002-07-26 Hiszton-dezacetiláz enzimet gátló hidroxámsav-származékok, mint új, citokin szintézist gátló gyulladás elleni gyógyszerek HUP0401167A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001733A ITMI20011733A1 (it) 2001-08-07 2001-08-07 Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
PCT/EP2002/008379 WO2003013493A1 (en) 2001-08-07 2002-07-26 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs

Publications (1)

Publication Number Publication Date
HUP0401167A2 true HUP0401167A2 (hu) 2004-11-29

Family

ID=11448251

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401167A HUP0401167A2 (hu) 2001-08-07 2002-07-26 Hiszton-dezacetiláz enzimet gátló hidroxámsav-származékok, mint új, citokin szintézist gátló gyulladás elleni gyógyszerek

Country Status (23)

Country Link
US (1) US20040157930A1 (hu)
EP (1) EP1414428B1 (hu)
JP (1) JP2005506320A (hu)
KR (1) KR20040035724A (hu)
CN (1) CN1538838A (hu)
AT (1) ATE435013T1 (hu)
BR (1) BR0212014A (hu)
CA (1) CA2456533A1 (hu)
CY (1) CY1109391T1 (hu)
DE (1) DE60232797D1 (hu)
DK (1) DK1414428T3 (hu)
ES (1) ES2328468T3 (hu)
HU (1) HUP0401167A2 (hu)
IL (1) IL160075A0 (hu)
IS (1) IS7124A (hu)
IT (1) ITMI20011733A1 (hu)
MX (1) MXPA04001190A (hu)
NO (1) NO20040513L (hu)
PL (1) PL365391A1 (hu)
PT (1) PT1414428E (hu)
RU (1) RU2004106605A (hu)
SI (1) SI1414428T1 (hu)
WO (1) WO2003013493A1 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7314953B2 (en) 2001-03-27 2008-01-01 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2003070188A2 (en) * 2002-02-15 2003-08-28 Sloan-Kettering Institute For Cancer Research Method of treating trx mediated diseases
JPWO2003070691A1 (ja) * 2002-02-21 2005-06-09 財団法人大阪産業振興機構 Ｎ−ヒドロキシカルボキサミド誘導体
ES2532607T3 (es) 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
US7456219B2 (en) 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CA2486303C (en) 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
AU2004230889B2 (en) * 2003-04-07 2008-03-13 Pharmacyclics Llc Hydroxamates as therapeutic agents
EP1491188A1 (en) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topical use of valproic acid for the prevention or treatment of skin disorders
DE602004026321D1 (de) * 2003-08-26 2010-05-12 Merck Hdac Res Llc Verwendung von SAHA zur Behandlung von Mesotheliom
DK1696898T3 (en) * 2003-12-02 2016-02-22 Univ Ohio State Res Found ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
US7368476B2 (en) * 2004-04-07 2008-05-06 Pharmacyclics, Inc. Hydroxamates as therapeutic agents
WO2006017214A2 (en) * 2004-07-12 2006-02-16 Merck & Co., Inc. Inhibitors of histone deacetylase
GB2417682A (en) * 2004-08-18 2006-03-08 Univ East Anglia Histone deacetylse inhibitor for treating connective tissue disorders
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
WO2007109178A2 (en) 2006-03-16 2007-09-27 Pharmacyclics, Inc. Indole derivatives as inhibitors of histone deacetylase
US20110150825A1 (en) * 2006-11-14 2011-06-23 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
US7820711B2 (en) * 2006-11-14 2010-10-26 Pharmacyclics Inc. Uses of selective inhibitors of HDAC8 for treatment of T-cell proliferative disorders
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
EA201201640A1 (ru) 2007-01-30 2013-09-30 Фармасайкликс, Инк. Способы определения устойчивости рака к ингибиторам гистондеацетилазы
US9827212B2 (en) * 2009-03-18 2017-11-28 The Trustees Of The University Of Pennsylvania Compositions and methods for treating asthma and other lung diseases
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
WO2011018241A1 (en) * 2009-08-14 2011-02-17 Cellzome Ag Methods for the identification and characterization of hdac interacting compounds
WO2012018499A2 (en) * 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
AU2012226586B2 (en) * 2011-03-09 2017-04-13 Cereno Scientific Ab Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
CN107007580A (zh) * 2012-02-03 2017-08-04 意大发马克股份公司 用于治疗肌肉萎缩症的化合物
CN102793693A (zh) * 2012-09-07 2012-11-28 天津医科大学 伏立诺他在制备治疗自身免疫及炎症性疾病药物方面的应用
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US5318964A (en) * 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
KR100231230B1 (ko) * 1995-08-08 1999-11-15 우에노 도시오 히드록삼산 유도체(hydroxamic acid derivatives)
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
IT1283637B1 (it) * 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
AU2002243231A1 (en) * 2000-11-21 2002-07-24 Wake Forest University Method of treating autoimmune diseases

Also Published As

Publication number Publication date
CN1538838A (zh) 2004-10-20
EP1414428B1 (en) 2009-07-01
ITMI20011733A1 (it) 2003-02-07
SI1414428T1 (sl) 2009-10-31
IS7124A (is) 2004-01-26
ITMI20011733A0 (it) 2001-08-07
WO2003013493A1 (en) 2003-02-20
KR20040035724A (ko) 2004-04-29
JP2005506320A (ja) 2005-03-03
PT1414428E (pt) 2009-08-25
CA2456533A1 (en) 2003-02-20
PL365391A1 (en) 2005-01-10
WO2003013493A8 (en) 2004-02-26
NO20040513L (no) 2004-03-24
CY1109391T1 (el) 2014-07-02
BR0212014A (pt) 2004-08-03
MXPA04001190A (es) 2005-02-17
DK1414428T3 (da) 2009-08-31
RU2004106605A (ru) 2005-05-10
ES2328468T3 (es) 2009-11-13
DE60232797D1 (de) 2009-08-13
ATE435013T1 (de) 2009-07-15
EP1414428A1 (en) 2004-05-06
US20040157930A1 (en) 2004-08-12
IL160075A0 (en) 2004-06-20

Similar Documents

Publication Publication Date Title
HUP0401167A2 (hu) Hiszton-dezacetiláz enzimet gátló hidroxámsav-származékok, mint új, citokin szintézist gátló gyulladás elleni gyógyszerek
NO20061253L (no) Acetylenderivater som inhibitorer av histon deacetylase
PH12017501383A1 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
NO20055216D0 (no) Nye hydroksamater som terapeutiske midler
DK1692097T3 (da) Tricykliske hydroxamat- og benzamidderivater, sammensætninger og fremgangsmåder
WO2003062191A8 (en) N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
WO2003066579A3 (en) Novel bicyclic hydroxamates as inhibitors of histone deacetylase
NO20051107L (no) Substituerte tienylhydroksaminsyrer og deres anvendelse til behandling av sykdommer forbundet med enzymatisk histondeacetylueaktivitet
AU2003219595A8 (en) Alpha,beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
WO2021127487A3 (en) Novel il2 agonists and methods of use thereof
CY1126110T1 (el) Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6
EP2450048A3 (en) Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
AU2003292888A1 (en) Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
NO20051138L (no) Nye farmasoytiske formuleringer av modafinil
PL377696A1 (pl) Enancjomery pochodnych kwasu tiofenohydroksamowego i ich zastosowanie jako inhibitorów HDAC
DK0966424T3 (da) Aminobenzophenoner som inhibitorer for interleukin og TNF
ITMI20031311A1 (it) Formulazioni per il trattamento di disturbi artrosici.
EA202190077A1 (ru) Ингибиторы гистондеацетилазы
McLaughlin et al. Histone deacetylase inhibitors in psoriasis therapy
WO2020068950A8 (en) Hdac1,2 inhibitors
DK1404304T3 (da) Tablet omfattende cetirizin og pseudoephedrin
MD3664802T2 (ro) Inhibitori biciclici ai deacetilazei histonei
DK1828160T3 (da) Cykliske sulfonylaminoderivater og anvendelse deraf som MMP-hæmmere
NO20053023L (no) Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees